How much does one dose of Carfilzomib cost?

Carfilzomib is a drug that belongs to the proteasome inhibitor class and is commonly used to treat multiple myeloma (Multiple Myeloma) and other related blood cancers. Multiple myeloma is a cancer that originates from plasma cells in the bone marrow, which proliferate abnormally, causing damage to the bone marrow and producing abnormal proteins in the skeletal system.

Carfilzomib has been launched in China and is included in medical insurance. Patients can purchase it domestically at a price of around 8,000 to 9,000 yuan. Please consult the local hospital pharmacy for specific prices. In foreign countries, the original drug of carfilzomib is mainly available, and the cheaper version is the European version of the original drug, which costs around 5,000. And the medicinal ingredients and efficacy are the same as those of domestic original medicines.

Carfilzomib's primary mechanism of action involves inhibition of the proteasome, a key mechanism for intracellular protein degradation. By interfering with the function of the proteasome, carfilzomib prevents protein degradation and waste excretion within cancer cells, causing cancer cells to accumulate toxic substances and ultimately leading to their death. This mechanism makes carfilzomib a powerful therapeutic tool, especially for those patients with multiple myeloma who have developed resistance to other treatments.

Carfilzomib is usually given to patients via injection to ensure effective delivery of the drug into the body while reducing the risk of drug metabolism and breakdown. Although this drug has made significant progress in the treatment of multiple myeloma, it may be associated with side effects such as low platelets, heart problems, and abnormal kidney function. Therefore, patients usually need to receive treatment under the close supervision of a doctor to ensure optimal treatment results and minimize adverse effects.

Overall, carfilzomib represents an innovation in the field of cancer treatment and is expected to improve the survival rate and quality of life of patients with multiple myeloma through precise intervention in intracellular biological processes.